Literature DB >> 6480832

Disruption of the purine nucleotide cycle by inhibition of adenylosuccinate lyase produces skeletal muscle dysfunction.

J L Swain, J J Hines, R L Sabina, O L Harbury, E W Holmes.   

Abstract

Controversy exists as to whether the purine nucleotide cycle is important in normal skeletal muscle function. Patients with disruption of the cycle from a deficiency of AMP deaminase exhibit variable degrees of muscle dysfunction. An animal model was used to examine the effect of inhibition of the purine nucleotide cycle on muscle function. When the compound 5-amino-4-imidazolecarboxamide riboside (AICAriboside) is phosphorylated to the riboside monophosphate in the myocyte it is an inhibitor of adenylosuccinate lyase, one of the enzymes of the purine nucleotide cycle. AICAriboside was infused in 28 mice, and 22 mice received saline. Gastrocnemius muscle function was assessed in situ by recording isometric tension developed during stimulation. The purine nucleotide content of the muscle was measured before and after stimulation. Disruption of the purine nucleotide cycle during muscle stimulation was evidenced by a greater accumulation of adenylosuccinate, the substrate for adenylosuccinate lyase, in the animals receiving AICAriboside (0.60 +/- 0.10 vs. 0.05 +/- 0.01 nmol/mumol total creatine, P less than 0.0001). There was also a larger accumulation of inosine monophosphate in the AICAriboside vs. saline-treated animals at end stimulation (73 +/- 6 vs. 56 +/- 5 nmol/mumol total creatine, P less than 0.03). Inhibition of flux through the cycle was accompanied by muscle dysfunction during stimulation. Total developed tension in the AICAriboside group was 40% less than in the saline group (3,023 +/- 1,170 vs. 5,090 +/- 450 g . s, P less than 0.002). An index of energy production can be obtained by comparing the change in total phosphagen content per unit of developed tension in the two groups. This index indicates that less high energy phosphate compounds were generated in the AICAriboside group, suggesting that interruption of the purine nucleotide cycle interfered with energy production in the muscle. We conclude from these studies that defective energy generation is one mechanism whereby disruption of the purine nucleotide cycle produces muscle dysfunction.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6480832      PMCID: PMC425310          DOI: 10.1172/JCI111553

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  26 in total

1.  The purine nucleotide cycle. Control of phosphofructokinase and glycolytic oscillations in muscle extracts.

Authors:  K Tornheim; J M Lowenstein
Journal:  J Biol Chem       Date:  1975-08-25       Impact factor: 5.157

2.  The purine nucleotide cycle. Studies of ammonia production by skeletal muscle in situ and in perfused preparations.

Authors:  M N Goodman; J M Lowenstein
Journal:  J Biol Chem       Date:  1977-07-25       Impact factor: 5.157

3.  Purine nucleotide cycle. Evidence for the occurrence of the cycle in brain.

Authors:  V Schultz; J M Lowenstein
Journal:  J Biol Chem       Date:  1976-01-25       Impact factor: 5.157

4.  The purine nucleotide cycle. 3. Oscillations in metabolite concentrations during the operation of the cycle in muscle extracts.

Authors:  K Tornheim; J M Lowenstein
Journal:  J Biol Chem       Date:  1973-04-25       Impact factor: 5.157

5.  The purine nucleotide cycle. IV. Interactions with oscillations of the glycolytic pathway in muscle extracts.

Authors:  K Tornheim; J M Lowenstein
Journal:  J Biol Chem       Date:  1974-05-25       Impact factor: 5.157

6.  The purine nucleotide cycle. The production of ammonia from aspartate by extracts of rat skeletal muscle.

Authors:  K Tornheim; J M Lowenstein
Journal:  J Biol Chem       Date:  1972-01-10       Impact factor: 5.157

7.  The effect of 2,4-dinitrofluorobenzene on the activity of striated muscle.

Authors:  A A Infante; R E Davies
Journal:  J Biol Chem       Date:  1965-10       Impact factor: 5.157

8.  Biochemical genetics of Chinese hamster cell mutants with deviant purine metabolism. VI. Enzymatic studies of two mutants unable to convert inosinic acid to adenylic acid.

Authors:  A S Tu; D Patterson
Journal:  Biochem Genet       Date:  1977-02       Impact factor: 1.890

9.  The purine nucleotide cycle in skeletal muscle.

Authors:  J M Lowenstein; M N Goodman
Journal:  Fed Proc       Date:  1978-07

10.  AMP deamination and IMP reamination in working skeletal muscle.

Authors:  R A Meyer; R L Terjung
Journal:  Am J Physiol       Date:  1980-07
View more
  13 in total

Review 1.  Small molecule adenosine 5'-monophosphate activated protein kinase (AMPK) modulators and human diseases.

Authors:  Sandeep Rana; Elizabeth C Blowers; Amarnath Natarajan
Journal:  J Med Chem       Date:  2014-08-28       Impact factor: 7.446

2.  5-Aminoimidazole-4-carboxamide riboside induces apoptosis in Jurkat cells, but the AMP-activated protein kinase is not involved.

Authors:  José M López; Antonio F Santidrián; Clara Campàs; Joan Gil
Journal:  Biochem J       Date:  2003-03-15       Impact factor: 3.857

3.  Myoadenylate deaminase deficiency: successful symptomatic therapy by high dose oral administration of ribose.

Authors:  N Zöllner; S Reiter; M Gross; D Pongratz; C D Reimers; K Gerbitz; I Paetzke; T Deufel; G Hübner
Journal:  Klin Wochenschr       Date:  1986-12-15

4.  Purification of adenylosuccinate lyase from rat skeletal muscle by a novel affinity column. Stabilization of the enzyme, and effects of anions and fluoro analogues of the substrate.

Authors:  P J Casey; J M Lowenstein
Journal:  Biochem J       Date:  1987-09-01       Impact factor: 3.857

5.  Ergometer exercise in myoadenylate deaminase deficient patients.

Authors:  M Gross; U Gresser
Journal:  Clin Investig       Date:  1993-06

6.  Excess purine degradation in exercising muscles of patients with glycogen storage disease types V and VII.

Authors:  I Mineo; N Kono; T Shimizu; N Hara; Y Yamada; S Sumi; K Nonaka; S Tarui
Journal:  J Clin Invest       Date:  1985-08       Impact factor: 14.808

7.  Genetic and metabolomic analysis of AdeD and AdeI mutants of de novo purine biosynthesis: cellular models of de novo purine biosynthesis deficiency disorders.

Authors:  Nathan Duval; Kyleen Luhrs; Terry G Wilkinson; Veronika Baresova; Vaclava Skopova; Stanislav Kmoch; Guido N Vacano; Marie Zikanova; David Patterson
Journal:  Mol Genet Metab       Date:  2013-01-12       Impact factor: 4.797

8.  Utilization of [15N]glutamate by cultured astrocytes.

Authors:  M Yudkoff; I Nissim; K Hummeler; M Medow; D Pleasure
Journal:  Biochem J       Date:  1986-02-15       Impact factor: 3.857

9.  Z-nucleotide accumulation in erythrocytes from Lesch-Nyhan patients.

Authors:  Y Sidi; B S Mitchell
Journal:  J Clin Invest       Date:  1985-12       Impact factor: 14.808

10.  5-aminoimidazole-4-carboxamide Riboside Induces Apoptosis Through AMP-activated Protein Kinase-independent and NADPH Oxidase-dependent Pathways.

Authors:  Sae Mi Wi; Ki-Young Lee
Journal:  Immune Netw       Date:  2014-10-22       Impact factor: 6.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.